Compare Nuvalent Inc (NUVL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Novartis AG — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 29.6× Nuvalent Inc's market cap, and Novartis AG pays a 3.17% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | NVS | |
|---|---|---|
Market Cap | $9.81B | $290.25B |
Sector | Technology | Health |
52-Week High | $123.96 | $168.62 |
52-Week Low | $72.16 | $113.50 |
Enterprise Value | $8.52B | $330.27B |
Dividend Yield | — | 3.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
